Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + Dexamethasone in mCRPC
NCT03432949Phase 4Active, not recruiting
- Sponsor
- University Health Network
- Start
- Feb 2018
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Standard of Care Radium-223 with Radium-223 + Dexamethasone (2 arms). Primary endpoint: Percentage of total doses delivered on schedule at 24 weeks. Started Feb 2018; status: active, not recruiting.
02
Drugs
dexamethasone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03432949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432949.